An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension - Full Text View

An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension

This study has been terminated.

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00449111

Purpose

Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.

Condition	Intervention	Phase
Hypertension	Drug: MK0954, losartan potassium / Duration of Treatment - 12 weeks	Phase III

MedlinePlus related topics:

High Blood Pressure

Drug Information available for:

Hydrochlorothiazide Losartan Losartan potassium Potassium chloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment

Official Title:	An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension

Further study details as provided by Merck:

Primary Outcome Measures:

Change of diastolic blood pressure after 6 weeks of treatment with cozaar plus

Estimated Enrollment:	138
Study Start Date:	January 2007

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patient treated with valsartan 80mg or irbesartan 150mg or vandesartan 8mg for at least 4 weeks prior to visit 1
Patient with systolic blood pressure between 140 to 159 mmhg and diastolic pressure between 90 to 99mmhg taken at visit 1

Exclusion Criteria:

History of angina pectoris that has not been stabilized in the past 6 weeks
History of clinically significant abnormal lab results or diseases
Myocardial infarction within the past 6 months
Stroke in the past 6 months

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00449111

Sponsors and Collaborators

Merck

Investigators


Study Director:	Medical Monitor	Merck

More Information

Study ID Numbers:	2007_005
First Received:	March 16, 2007
Last Updated:	March 16, 2007
ClinicalTrials.gov Identifier:	NCT00449111
Health Authority:	Korea: Food and Drug Administration

Study placed in the following topic categories:

Losartan

Vascular Diseases

Essential hypertension

Angiotensin II

Hydrochlorothiazide

Hypertension

Additional relevant MeSH terms:

Molecular Mechanisms of Pharmacological Action

Diuretics

Physiological Effects of Drugs

Sodium Chloride Symporter Inhibitors

Cardiovascular Agents

Antihypertensive Agents

Pharmacologic Actions

Membrane Transport Modulators

Angiotensin II Type 1 Receptor Blockers

Natriuretic Agents

Therapeutic Uses

Cardiovascular Diseases

Anti-Arrhythmia Agents

ClinicalTrials.gov processed this record on November 20, 2008